Presentations
& Publications
Publications
-
Journal of Clinical Oncology (2023)
Preliminary efficacy, safety, and immunomodulatory effects of PT-112 from a phase 2 proof of concept study in patients (pts) with thymic epithelial tumors (TETs)
-
Journal of Clinical Oncology - ASCO GU (2023)
A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer
-
eClinical Medicine, The Lancet (2022)
Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours
-
ESMO IOTECH (2022)
A phase IIa study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab (“PAVE”) in advanced non-small cell lung cancer (NSCLC) patients (pts)
-
Cancers (2022)
PT-112 Induces Mitochondrial Stress and Immunogenic Cell Death, Targeting Tumor Cells with Mitochondrial Deficiencies
-
Cancer Research (2022)
PT-112 induces potent mitochondrial stress and immunogenic cell death in human prostate cancer cell lines.
-
European Journal of Cancer (2022)
Characterization of differential metabolic phenotypes and PT-112-induced mitochondrial effects in human prostate cancer cells
-
Journal for ImmunoTherapy of Cancer (2022)
Immunologically relevant effects of PT-112 on cancer cell mitochondria
-
OncoImmunology (2020)
PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models.
-
Journal of Clinical Oncology (2020)
PT-112 in Advanced metastatic castrate-resistant prostate cancer (mCRPC), as monotherapy or in combination with PD-L1 inhibitor avelumab: findings from two Phase I studies.
-
Annals of Oncology (2020) - Mini Oral Presentation
Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours.
-
Blood (2020) - ASH Oral Poster Presentation
A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma.
-
Annals of Oncology (2018) - Winner "Best Poster" Developmental Therapeutics
PT-112: A Well-Tolerated Novel Immunogenic Cell Death (ICD) Inducer with Activity in Advanced Solid Tumors.
-
Blood (2017)
Translational Research of PT-112, a Clinical Agent in Advanced Phase I Development: Evident Bone Tropism, Synergy In Vitro with Bortezomib and Lenalidomide, and Potent Efficacy in the Vk*MYC Mouse Model Myeloma.
-
American Association for Cancer Research (2017)
A kinome analysis of the molecular pharmacodynamics of the PT-112 in a human cancer cell line.
-
European Journal of Cancer (2016)
Potent induction of immunogenic cell death by PT-112.
Posters
PT-112, a First-in-Class Pyrophosphate-Platinum Conjugate, Selectively Targets Highly Glycolytic Tumor Cells (ENA 2020)
PT-112 in advanced metastatic castrate-resistant prostate cancer (mCRPC), as monotherapy or in combination with PD-L1 inhibitor avelumab: findings from two Phase I studies (ASCO GU 2020)
Potent induction of immunogenic cell death by PT-112 (CRI-CIMT-EATI-AACR 2018)
Translational Research of PT-112, a Clinical Agent in Advanced Phase I Development: Evident Bone Tropism, Synergy In Vitro with Bortezomib and Lenalidomide, and Potent Efficacy in the Vk*MYC Mouse Model of Multiple Myeloma (ASH 2017)
PT-112: A Well-Tolerated Novel Immunogenic Cell Death (ICD) Inducer with Activity in Advanced Solid Tumors (ESMO 2018)
A kinome analysis of the molecular pharmacodynamics of PT-112 in a human cancer cell line (AACR 2017)
A Phase I Study of PT-112 in Advanced Solid Tumors (ASCO 2017)
Findings across pre-clinical models in the development of PT-112, a novel investigational platinum-pyrophosphate anti-cancer agent (EORTC-NCI-AACR 2016)